Yet, Schmalbrock and colleagues’ comprehensive study to uncover the genetic causes of midostaurin resistance in FLT3–ITD-mutated AML found that only 11% of patients showed secondary FLT3–ITD mutations in relapsed or refractory AML. Here, FLT3 is linked to acute myeloid leukemia.